Olive Diagnostics

Olive Diagnostics has developed a noninvasive passive urinalysis sensor that provides real-time health alerts, early detection, and information on disease progression. Using optics for data collection, the sensor is mounted inside the toilet and does not require further intervention. The sensor detects the composition of the urine and sends the data to the cloud. AI algorithms then process the sample to detect the molecular composition and characteristics of the urine. The findings are sent back to either the user via a mobile application or the user’s medical supervisor, and the biomarker data is also sent directly to the electronic health record system for physician and provider accessibility. The device monitors the duration and biomarkers for hydration; pregnancy; ovulation; red blood cells (for early detection of kidney stones); white blood cells (for detection of urinary tract infections); protein (related to preeclampsia, infections, prediabetes, and diabetes); electrolytes; changes in urination patterns, including volume, time of day, frequency, and duration; glucose; ketones; and specific gravity (for hepatorenal syndrome).

Olive Diagnostics has raised $11.75M in total funding across 7 rounds. The company is currently at the Seed stage. Key investors include Keren Maccabi, eHealth Ventures, Mekorot.

Olive Diagnostics was founded in 2019 by Guy Goldman (Founder & CEO).

Olive Diagnostics operates in Health Tech & Life Sciences, Digital Healthcare, Digital Medical Diagnostics, Medical Devices, Diagnostics Devices, with core technologies in Data Storage, Cloud, Artificial Intelligence, Sensing, Optic. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Laboratories, Patients, Consumers, Demographics & Family, Seniors.

Olive Diagnostics is based in Avraham Elmali'akh Street 149, Jerusalem, Israel, Jerusalem District.